Eledon Pharmaceuticals Inc ELDN
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if ELDN is a good fit for your portfolio.
News
-
Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results
-
Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection
-
Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human
-
Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Trading Information
- Previous Close Price
- $1.57
- Day Range
- $1.55–2.00
- 52-Week Range
- $1.07–2.95
- Bid/Ask
- $2.10 / $2.14
- Market Cap
- $49.38 Mil
- Volume/Avg
- 400,123 / 76,586
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- —
Company Profile
Eledon Pharmaceuticals Inc is a clinical-stage biotechnology company. The firm is focused on transplantation and autoimmune diseases. It targets CD40L pathway to develop potential treatments for patients living with an autoimmune disease, patients requiring an organ or cell-based transplant, and for patients living with ALS. The company's compound in development is tegoprubart, an IgG1, anti-CD40L antibody with high affinity for the CD40 Ligand, a well-validated biological target that has broad therapeutic potential.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 20
- Website
- https://www.eledon.com
Valuation
|
Metric
|
ELDN
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.57 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
ELDN
Financial Strength
|
Metric
|
ELDN
|
|---|---|
Quick Ratio | 13.12 |
Current Ratio | 14.41 |
Interest Coverage | — |
Quick Ratio
ELDN
Profitability
|
Metric
|
ELDN
|
|---|---|
Return on Assets (Normalized) | −36.17% |
Return on Equity (Normalized) | −38.95% |
Return on Invested Capital (Normalized) | −38.69% |
Return on Assets
ELDN
Biotechnology Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
NVO
| Novo Nordisk A/S ADR | Znfycvxwhs | Bqrjl | $550.4 Bil | |
VRTX
| Vertex Pharmaceuticals Inc | Bnmglzcw | Wblxqf | $101.7 Bil | |
REGN
| Regeneron Pharmaceuticals Inc | Qndpzsdxb | Hcbymjx | $98.1 Bil | |
MRNA
| Moderna Inc | Hhcdbhjnm | Krly | $39.1 Bil | |
ARGX
| argenx SE ADR | Fwydgmh | Gmwd | $21.7 Bil | |
BNTX
| BioNTech SE ADR | Dkrwqjpt | Mkj | $20.8 Bil | |
ALNY
| Alnylam Pharmaceuticals Inc | Fqljkwr | Lqqpkm | $18.4 Bil | |
BMRN
| Biomarin Pharmaceutical Inc | Vcfpdfdlb | Xlpzzl | $17.1 Bil | |
RPRX
| Royalty Pharma PLC Class A | Hnbzqxfsf | Fmpfml | $12.5 Bil | |
INCY
| Incyte Corp | Yylpvjmnf | Tthbn | $11.9 Bil |